Dr. Stephen J. Freedland spoke at the 25th International Prostate Cancer Update on Friday, January 23, 2015 on “Biochemical Failure After Treatment.”
Presentation
Keywords: PSA recurrence, risk stratification, hormonal therapy
How to cite: Freedland, Stephen J. “Biochemical Failure After Treatment” Grand Rounds in Urology. April 13, 2015. Accessed Nov 2024. https://dev.grandroundsinurology.com/prostate-cancer-stephen-j-freedland-biochemical-failure-after-treatment/.
References
References
D’Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003 Sep 17;95(18):1376-83.
http://www.ncbi.nlm.nih.gov/pubmed/13130113
Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005 Jul 27;294(4):433-9.
http://www.ncbi.nlm.nih.gov/pubmed/16046649
Heidenreich A, Abrahamsson PA, Artibani W, et al. Early detection of prostate cancer: European Association of Urology recommendation. Eur Urol. 2013 Sep;64(3):347-54
http://www.ncbi.nlm.nih.gov/pubmed/23856038
Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007 Apr 20;25(12):1596-605.
http://www.ncbi.nlm.nih.gov/pubmed/17404365
Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999 May 5;281(17):1591-7.
http://www.ncbi.nlm.nih.gov/pubmed/10235151
Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008 Jun 18;299(23):2760-9.
http://www.ncbi.nlm.nih.gov/pubmed/18560003
ABOUT THE AUTHOR
Stephen J. Freedland, MD, is a Professor of Surgery and holds the Warschaw Robertson Law Families Chair in Prostate Cancer at Cedars-Sinai Medical Center in Los Angeles. He is also Director of the Center for Integrated Research in Cancer and Lifestyle, Co-Director of the Cancer Genetics and Prevention Program, and Associate Director of the Faculty Development Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai. Freedland is an expert on urological diseases, particularly benign prostatic hyperplasia and prostate cancer. He is interested in combining Western and holistic medicine for cancer treatment and prevention. His other research interests include urological diseases and the role of diet, lifestyle, and obesity in prostate cancer development and progression, as well as prostate cancer among racial groups and risk stratification for men with prostate cancer. Freedland has published over 400 studies in peer-reviewed journals. He is also a reviewer for more than 50 journals. He is on the editorial board for Cancer Prevention Research, European Urology, the International Journal of Urology, Nature Reviews Urology, and BJUI, and serves as Editor-in-Chief for Prostate Cancer and Prostatic Diseases and as a consulting editor for European Urology. Dr. Freedland earned his MD from the University of California, Davis. He completed a Residency in Urology at UCLA and a Fellowship in Urological Oncology at Johns Hopkins. Before joining Cedars-Sinai, he served as an Associate Professor of Urology at Duke University.
